Individuals with intellectual and developmental disabilities may also have mental health and substance use issues that are overlooked. At the same time, traditional behavioral health resources and interventions don’t always take into account the unique needs of someone with I/DD.
Do you have the resources and information you need to support the individuals who rely on your services in the most person-centered and holistic ways?
The American Network of Community Options and Resources (ANCOR) and NADD, an association for persons with developmental disabilities and mental health needs, are proud to partner together to offer this six-part webinar series that covers topics ranging from relaxation training for individuals with I/DD to supporting psychological resilience in staff.
Register for the Six-Part Series and Save 20%!
- ANCOR & NADD member: $331
- Non-member: $619
Note: must purchase the entire series via the link below to take advantage of the additional 20% discount
Many individuals with IDD and their families, as well as clinicians and researchers, believe that psychotropic medications, and particularly antipsychotic medications, have been over-prescribed to persons with IDD, often with little clinical justification, and without appropriate monitoring for toxicity. Psychotropic treatment of persons with IDD should start with an accurate psychiatric diagnosis; or in the absence of an agreed-upon diagnosis, a well-thought-out psychotropic treatment hypothesis. This program will briefly describe the history of psychotropic practice with persons with IDD, the current best-practice of establishing a diagnosis before prescribing medications, and the need for continuous monitoring of individuals for evidence of side effects or toxicity.
Stephen Ruedrich, MD
- ANCOR & NADD member: $69
- Non-member: $129